Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1.7 Billion USD | 72.44% |
| 2023 | 987 Million USD | 11.53% |
| 2022 | 885 Million USD | 25.35% |
| 2021 | 706 Million USD | 22.17% |
| 2020 | 577.9 Million USD | 12.87% |
| 2019 | 512 Million USD | 10.68% |
| 2018 | 462.6 Million USD | 14.9% |
| 2017 | 402.6 Million USD | 12.43% |
| 2016 | 358.1 Million USD | 6.17% |
| 2015 | 337.3 Million USD | 0.75% |
| 2014 | 334.8 Million USD | -1.7% |
| 2013 | 340.6 Million USD | 0.38% |
| 2012 | 339.3 Million USD | 13.14% |
| 2011 | 299.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 187 Million USD | -13.43% |
| 2024 FY | 808 Million USD | -18.14% |
| 2024 Q3 | 246 Million USD | 31.55% |
| 2024 Q4 | 224 Million USD | -8.94% |
| 2024 Q1 | 216 Million USD | -35.52% |
| 2023 Q4 | 335 Million USD | 63.41% |
| 2023 Q3 | 205 Million USD | -17.67% |
| 2023 Q2 | 249 Million USD | 25.76% |
| 2023 FY | 987 Million USD | 11.53% |
| 2023 Q1 | 198 Million USD | -18.18% |
| 2022 Q3 | 212 Million USD | -13.11% |
| 2022 FY | 885 Million USD | 25.35% |
| 2022 Q1 | 187 Million USD | 0.54% |
| 2022 Q4 | 242 Million USD | 14.15% |
| 2022 Q2 | 244 Million USD | 30.48% |
| 2021 Q4 | 186 Million USD | 7.7% |
| 2021 FY | 706 Million USD | 22.17% |
| 2021 Q3 | 172.7 Million USD | 4.35% |
| 2021 Q1 | 164.7 Million USD | 4.24% |
| 2021 Q2 | 165.5 Million USD | 0.49% |
| 2020 FY | 577.9 Million USD | 12.87% |
| 2020 Q3 | 136.1 Million USD | -3.48% |
| 2020 Q2 | 141 Million USD | -1.26% |
| 2020 Q4 | 158 Million USD | 16.09% |
| 2020 Q1 | 142.8 Million USD | -0.42% |
| 2019 FY | 512 Million USD | 10.68% |
| 2019 Q1 | 115.5 Million USD | -7.08% |
| 2019 Q2 | 123.2 Million USD | 6.67% |
| 2019 Q3 | 129.9 Million USD | 5.44% |
| 2019 Q4 | 143.4 Million USD | 10.39% |
| 2018 Q1 | 107 Million USD | -0.28% |
| 2018 Q4 | 124.3 Million USD | 6.24% |
| 2018 Q3 | 117 Million USD | 2.36% |
| 2018 Q2 | 114.3 Million USD | 6.82% |
| 2018 FY | 462.6 Million USD | 14.9% |
| 2017 Q2 | 96.2 Million USD | -2.04% |
| 2017 Q3 | 100.9 Million USD | 4.89% |
| 2017 Q4 | 107.3 Million USD | 6.34% |
| 2017 FY | 402.6 Million USD | 12.43% |
| 2017 Q1 | 98.2 Million USD | 9.72% |
| 2016 FY | 358.1 Million USD | 6.17% |
| 2016 Q2 | 93 Million USD | 13.14% |
| 2016 Q4 | 89.5 Million USD | -3.97% |
| 2016 Q1 | 82.2 Million USD | -5.41% |
| 2016 Q3 | 93.2 Million USD | 0.22% |
| 2015 FY | 337.3 Million USD | 0.75% |
| 2015 Q4 | 86.9 Million USD | 7.42% |
| 2015 Q1 | 81.4 Million USD | 3.56% |
| 2015 Q3 | 80.9 Million USD | -8.17% |
| 2015 Q2 | 88.1 Million USD | 8.23% |
| 2014 Q2 | 87.5 Million USD | 7.89% |
| 2014 FY | 334.8 Million USD | -1.7% |
| 2014 Q3 | 87.6 Million USD | 0.11% |
| 2014 Q1 | 81.1 Million USD | -8.77% |
| 2014 Q4 | 78.6 Million USD | -10.27% |
| 2013 Q3 | 83.7 Million USD | -2.9% |
| 2013 Q4 | 88.9 Million USD | 6.21% |
| 2013 FY | 340.6 Million USD | 0.38% |
| 2013 Q1 | 81.8 Million USD | 0.0% |
| 2013 Q2 | 86.2 Million USD | 5.38% |
| 2012 FY | 339.3 Million USD | 13.14% |
| 2011 FY | 299.9 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 616.19 Million USD | -176.213% |
| Bausch Health Companies Inc. | 5.23 Billion USD | 67.488% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -63.027% |
| Elanco Animal Health Incorporated | 1.61 Billion USD | -5.583% |
| Perrigo Company plc | 1.52 Billion USD | -11.351% |
| Teva Pharmaceutical Industries Limited | 4.45 Billion USD | 61.761% |
| Zoetis Inc. | 2.76 Billion USD | 38.445% |